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Abstract
Background: Guidelines recommend maintaining the heart rate (HR) of acute stroke patients within physiological
limits; data on the frequency and predictors of significant deviations from these limits are scarce.
Methods: Demographical data, stroke risk factors, NIH stroke scale score, lesion size and location, and ECG
parameters were prospectively assessed in 256 patients with ischemic stroke. Patients were continuously monitored
for at least 24 hours on a certified stroke unit. Tachycardia (HR ≥120 bpm) and bradycardia (HR <45 bpm) and
cardiac rhythm (sinus rhythm or atrial fibrillation) were documented. We investigated the influence of risk factors
on HR disturbances and their respective influence on dependence (modified Rankin Scale ≥ 3 after three months)
and mortality.
Results: HR ≥120 bpm occurred in 39 patients (15%). Stroke severity (larger lesion size/higher NIHSS-score on
admission), atrial fibrillation and HR on admission predicted its occurrence. HR <45 bpm occurred in 12 patients
(5%) and was predicted by lower HR on admission. Neither HR ≥120 nor HR <45 bpm independently predicted
poor outcome at three moths. Stroke location had no effect on the occurrence of HR violations. Clinical severity
and age remained the only consistent predictors of poor outcome.
Conclusions: Significant tachycardia and bradycardia are frequent phenomena in acute stroke; however they do
not independently predict clinical course or outcome. Continuous monitoring allows detecting rhythm
disturbances in stroke patients and allows deciding whether urgent medical treatment is necessary.
Background
Cardiac complications are frequent after acute stroke
and, vice versa, cardiac disease is a frequent cause of
stroke. About 30% of all strokes are classified as cardi-
oembolic with atrial fibrillation (AF) being the single
most important risk factor [1]. The prominent cardiac
complications are known since a long time and include
myocardial infarctions (MI), tachycardia, and bradycar-
dia [2]. Heart rate (HR) monitoring and maintenance of
a normal HR is an essential part of stroke unit treat-
ment [3,4]. However, in contrast to blood pressure, no
definition of what is a normal HR is given, and ques-
tions arise from this recommendation: What to do when
HR leave “physiological limits"? Is active treatment
necessary in any case? How frequent are significant
tachycardias or bradycardias in an unselected cohort of
stroke patients, and at which time point after stroke do
they occur? Are there predictors of tachy- or bradycar-
dia? And finally, are tachy- or bradycardia predictive of
poor outcome? Data on all these questions is scarce.
Methods
We included 256 consecutive patients with acute
ischemic stroke (< 48 h since symptom onset) admitted
to our stroke unit. Patients were classified according to
the TOAST criteria with respect of the presumptive
cause of stroke [5]. Patients with transient neurological
deficits were included in case imaging identified an
acute ischemic lesion consistent with the clinical
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for eligibility. Patients with sinus thrombosis (n = 6),
primary or secondary intracerebral haemorrhage (ICH,
n = 41), and patients with subarachnoid haemorrhage
(n = 5) were excluded. We excluded 17 patients, who
were intubated during the admission process for coma
or respiratory failure (n = 5) or for emergency interven-
tion demanding anaesthesia (intra-arterial thrombolysis/
mechanical thrombectomy, n = 12). We also excluded
patients who had to be intubated within 24 hours (n = 6)
and before any endpoint occurred, because in all these
cases the course of HR was biased by mechanisms other
than the natural course, e.g. adrenergic vasopressors to
maintain a sufficient blood pressure in sedated patients.
We excluded patients who spent <24 hours on the unit
(n = 34) and who were referred in stable conditions, as
for those only incomplete data sets were available.
The local ethics committee (Ethikkommission der
Ärztekammer Westfalen-Lippe) approved data collection
and a telephone interview after three months. Follow-up
data were provided by the “Qualitätssicherungsprojekt
Schlaganfall Nordwestdeutschland” (Quality control pro-
ject “Stroke” North-Western Germany).
All patients or their proxies gave informed consent to
the protocol at the start of the monitoring period.
Demographical data (age, sex, past medical history,
time from symptom onset) were assessed. History of
chronic heart failure (CHF), coronary heart disease
(CHD), AF, and other rhythm disturbances were
assessed. Vital signs (bood pressure, oxygen saturation)
and laboratory parameters (blood glucose, cholesterol,
Troponin I, Creatinine, C-reactive protein) were
assessed on admission.
Stroke severity on admission was determined using
the National Institute of Health Stroke Scale (NIHSS)
[6]. We also noted whether patients received thromboly-
tic therapy. Time from symptom onset was recorded in
full hours.
All patients received cerebral imaging (95% CCT, 69%
MRI) to determine lesion size and location. Lesion size
was categorized as follows: “1” No infarction visible on
scan but clinical symptoms persisting 24 hours or more.
“2” infarction <1.5 cm diameter, “3” size up to 1/3 of
MCA territory or 1.5-5 cm diameter. “4” lesion 1/3-2/3
MCA territory or >5 cm diameter but no space occupy-
ing effect. “5” >2/3 MCA territory or >5 cm diameter
plus space occupying effect [7].
Location of the infarction was also assessed on cere-
bral imaging and classified as “left” and “right” for the
left and right anterior circulation territory, “posterior”
for lesions only in the vertebro-basilar territory, “multi-
ple” for multiple lesions in more than one pre-defined
region and “undetermined” in case no definite new
lesion was seen.
Assessment of heart rate and rhythm
An ECG was recorded on admission and evaluated con-
cerning HR, type of rhythm, configuration and duration
of PQ-time, QRS-complex and ST-segment.
Rhythm was described as sinus rhythm or AF. Sinus
arryhthmia and atrial and ventricular premature beats
were classified as sinus rhythm.
PQ-time was defined as normal or AV-block. Length
of the QRS-complex and presence of a pathological
Q-wave was noted. The ST-segment was evaluated in
patients without branch blocks. Signs of left ventricular
hypertrophy (LVH) according to the modified Cornell
criteria, signs of chronic strain, and markers of old and
acute myocardial infarction were noted [8]. QTc-time
was calculated according to the Bazett’s-formula.
Acute coronary syndromes (ACS) were diagnosed
according to clinical and laboratory investigations. Con-
trol ECGs were performed if indicated [9,10].
Monitoring
Patients were connected to an automated multimodal
monitoring system (Siemens SC6000 or SC9000XL,
Siemens, Erlangen, Germany) using a three-lead ECG-
tracing method routinely displaying lead II of the Eintho-
ven leads. HR was continuously recorded. “Tachycardia”
was defined as HR ≥120 beats per minute (bpm), “brady-
cardia” was defined as HR <45 bpm. These thresholds
were arbitrarily chosen prior to the study after consented
decision of all authors as “HR that is significantly abnor-
mal and is likely to demand active medical treatment”.
The textbook definition of tachycardia (≥100 bpm) and
bradycardia (<60 bpm) were assessed for comparison rea-
sons. Only the first 24 hours were analysed concerning
HR threshold violations to determine the predictive value
obtainable in patients monitored for at least this period.
The exact timing of the first occurrence of brady- or
tachycardia was noted. All patients received echocardio-
graphy to assess left ventricular function as an important
predictor of outcome in patients with AF [11]. Left ven-
tricular function was graded as normal (ejection fraction,
EF >55%), moderately impaired (EF 35-55%) and severely
impaired (EF < 35%). Due to the small number of
patients with severely impaired EF, data were dichoto-
mised for analysis comparing patients with EF > 55% vs.
patients with lower EF. Infectious complications were
assessed as described elsewhere [7].
Treatment of tachycardia/Bradycadia
Active medical treatment was left to the discretion of the
treating physician, but was considered in case of “signifi-
cant” tachycardia or bradycardia as defined above.
Furthermore, any tachycardia or bradycardia with clinical
symptoms (dizziness, palpitation, pain, systolic BP < 100
mmHg) was considered significant irrespective of the
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necessary, this was defined as the end point heart rhythm
disturbance, HRD. The occurrence of HRDs was
recorded for the complete stay in the hospital even
beyond 24 hours.
Tachycardic HRD was treated depending on the type of
rhythm disturbance. The most frequent type of tachyar-
rhythmia secondary to AF was treated by metoprolol i.v.
(5 mg iv. shot or via continuous infusion, 50 mg/50 ml, at
a rate of 2-8 ml/h). Alternatively verapamil i.v. was given
(5-10 mg i.v. shot, or continuous infusion 50 mg/50 ml, at
a rate of 2-8 ml/h). In addition, digoxin preparations were
given iv (0.25 mg, tid for 3 days, thereafter according to
serum levels). Pharmakologic cardioversion was performed
by amiodarone (900 mg/d iv for 5 days followed by
200 mg/d) or electric cardioversion, the latter especially in
cases of instable blood pressure. Bradycardia was only
treated, if associated with clinical symptoms or in case of
RR intervals >5 s. The first action included atropine
(0.1 mg i.v.), attachable external pacer electrodes were
placed in selected cases. Indication for permanent pace-
maker placement was discussed with the cardiologist.
Other rhythm disturbances were treated according to
established guidelines for advanced cardiac life support.
Follow-up
Patients were followed-up clinically throughout their hos-
pital stay and after discharge by validated standardized tel-
ephone interviews 3 months after symptom onset to
determine clinical outcome [6]. Outcome was determined
using the modified Rankin scale (mRS). Dependency was
defined as mRS ≥3. Mortality was noted separately.
Statistics
Patients with tachycardia or bradycardia were compared
with patients without events. Single factor analysis was
performed using Fisher’s exact test for dichotomized
items and Chi-square for trend analysis for ordinal
items. Mann-Whitney-U tests were performed for con-
tinuous variables. HR values obtained at various time
points during the first 24 hours were compared using
the Wilcoxon Test for matched pairs.
Multiple logistic regression analysis was used to deter-
mine independent predictors of HRDs, infectious com-
plications and bad outcome which always included the
HR threshold with the models. Lesion size (ordinal 0-5)
but not NIHSS on admission was included in these
models. Frequency and timing of tachycardia and brady-
cardia within the first 24 hours were graphically dis-
played cumulative percentages. Patients
Results
Basic demographical data of the study population and of
the patients who had to be excluded, because they did
not complete the 24 study period as described above are
given in table 1.
Patients who had to be excluded from the final analy-
sis had longer times to admission (p = 0.01), had lower
heart rates on admission (0.04) and had lower NIHSS
scores on admission (p < 0.001). However, those
patients that had to be excluded because of clinical dete-
rioration and subsequent intubation had significantly
higher NIHSS scores on admission (15, 7.5-15.5 vs. 5, 2-
9; p < 0.01).There were no significant differences in
other demographical parameters.
Detailed data of single factor analysis results of the
study population are given in table 2.
Both, mild and severe tachycardia was significantly
more frequent in patients with a history of AF or AF on
admission ECG than in patients without AF, with a
Table 1 Basic demographical data of study population
and excluded patients
Study population
(n = 256)
Excluded stroke
patinets (n = 40)
p
Male 135 (53) 25 (63) n.s.
Age [years] 70 (61-76,5) 67 (55,25-73,25) n.s.
time to
admission [h]
2,3 (1,1-6,0) 3,00 (2,3-11,0) 0,01
NIHSS 5 (2-9) 1 (1-3,25) 0.0001
Lesion size 2 (2-3) 2 (1-3) 0.05
Infarction site:
Right
73 (29) 11 (28) n.s.
left 98 (38) 10 (25)
posterior 47 (18) 11 (28)
multiple 4 (10) 1 (3)
none 28 (11) 7 (18)
aHT 193 (75) 27 (68) n.s.
COPD 16 (6) 3 (8) n.s.
DM 60 (23) 7 (18) n.s.
CHOL 53 (21) 8 (20) n.s.
STROKE 54 (21) 12 (30) n.s.
MI 15 (6) 4 (10) n.s.
CHF 24 (9) 4 (10) n.s.
CAD 43 (17) 11 (28) n.s.
AF 62 (24) 6 (15) n.s.
1. BP syst
[mmHg]
160 (140-180) 156 (146-170) n.s.
1. BP diast
[mmHg]
88 (78,75-99) 89,5 (81,5-92,75) n.s.
SaO2 [%] 97 (95-98) 98,5 (97-100) n.s.
GCS 15 (15-15) 15 (14-15) n.s.
HR [bpm] 80 (68-90) 72,5 (64-83,5) 0.04
thrombolysis 52 (20) 4 (10) n.s.
aHT - arterial hypertension, COPD - chronic obstructive pulmonary disease,
CHF - chronic heart failure, CHD - coronary heart disease, AF - atrial
fibrillation, BP - blood pressure, HR - heart rate, GCS - Glasgow Coma Scale.
Ordinal and continuous variables are median (IQR), dichotomous variables are
n(%).
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<45 bpm (n
= 12)
≥45 (n = 244) p ≥120 (n = 39) <120 (n =
217)
p ≥100 (n = 87) <100 (n =
169)
p ≥60 (n = 142) <60 (n = 114) p
Male 8 (67) 127 (52) n.s. 23 (59) 112 (52) n.s. 45 (52) 90 (53) n.s. 67 (47) 68 (60) 0.06
Age [years] 72,5 (64,5-79) 70 (61-79) n.s. 74 (64,5-78) 70 (59-78) 0.09 69 (62-77) 71 (59-79) n.s. 70 (61-78) 72 (62-78) n.s.
time to
admission [h]
1,8 (1,1-3,2) 2,3 (1,2-3,2) n.s. 1,8 (1,1-3,4) 2,5 (1,2-6,8) n.s. 2 (1,1-5,6) 2,5 (1,2-7,1) n.s. 2 (1,1-5,8) 2,6 (1,2-7) n.s.
NIHSS 3 (2-8) 5 (2-9) n.s. 7 (3,5-12,5) 4 (2-8) 0.003 6 (3-11,5) 4 (2-7) 0.0004 5,5 (2-9) 4 (2-8) n.s.
infarction site:
right
4 (33) 69 (28) n.s. 11 (28) 62 (29) n.s. 22 (25) 51 (30) 0.06 42 (30) 31 (27) n.s.
left 5 (33) 94 (38) 20 (51) 78 (36) 42 (48) 56 (33) 57 (40) 41 (36)
posterior 3 (25) 44(18) 5 (13) 42 (19) 16 (18) 31 (18) 24 (17) 23 (20)
multiple 0 10 (4) 1 (3) 9 (4) 3 (3) 7 (4) 7 (5) 3 (3)
none 1 (8) 27 (11) 2 (5) 27 (12) 4 (5) 25 (15) 12 (8) 16 (14)
Lesion size 2,5 (2-3) 2 (2-3) n.s. 3 (2-4) 2 (2-3) <0.0001 3 (2-3) 2 (2-3) 0.01 2 (2-3) 2 (2-3) n.s.
aHT 10 (83) 183 (75) n.s. 33 (85) 160 (74) n.s. 72 (83) 121 (72) 0.06 111 (78) 82 (72) n.s.
COPD 0 16 (7) n.s. 3 (8) 13 (6) n.s. 6 (7) 10 (6) n.s. 11 (8) 5 (4) n.s.
DM 3 (25) 44 (18) n.s. 5 (13) 55 (25) n.s. 16 (18) 44 (26) n.s. 36 (25) 24 (21) n.s.
CHOL 4 (33) 49 (20) n.s. 4 (10) 49 (23) 0.08 14 (16) 39 (23) n.s. 24 (17) 29 (25) n.s.
STROKE 5 (43) 49 (20) 0.13 8 (21) 46 (21) n.s. 17 (20) 37 (22) n.s. 28 (20) 26 (23) n.s.
MI 1 (8) 14 (6) n.s. 2 (5) 13 (6) n.s. 3 (3) 12 (7) n.s. 6 (4) 9 (8) n.s.
CHF 2 (17) 22 (9) n.s. 1 (3) 23 (11) n.s. 5 (6) 19 (11) n.s. 13 (9) 11 (10) n.s.
CAD 3 (25) 40 (16) n.s. 7 (18) 36 (17) n.s. 15 (17) 28 (17) n.s. 22 (15) 21 (18) n.s.
AF 5 (42) 57 (23) n.s. 23 (59) 39 (18) <0.0001
(OR 6.6;
3.2-13.5)
36 (41) 26 (15) <0.0001 (OR
3.9; 2.1-7.0)
38 (27) 24 (21) n.s.
Vital signs/
admission
1. BP syst
[mmHg]
167 (140-184) 160 (140-180) n.s. 163 (140-180) 160 (140-180) n.s. 160 (140-181) 160 (140-180) n.s. 160 (140-180) 164 (140-180) n.s.
1. BP diast
[mmHg]
80 (73-97) 88,5 (80-99) n.s. 90 (80-100) 85 (75-96) 0.04 90 (80-100) 85 (75-95) 0.04 90 (80-100) 83 (76-95) 0.07
SaO2 [%] 98,5 (97-99) 97 (95-97) n.s. 97 (95-98) 97 (95-98) n.s. 97 (95-98) 97 (96-98) n.s. 97 (95-98) 98 (96-98) n.s.
GCS 15 (13-15) 15 (15-15) n.s. 15 (12,5-15) 15 (15-15) n.s. 15 (15-15) 15 (13-15) n.s. 15 (14-15) 15 (15-15) n.s.
HR [bpm] 54,5 (50-68) 80 (70-90) <0.0001 104 (88,5-121) 77 (65-85) <0.0001 92 (80-108) 74 (65-80) <0.0001 85 (77-97) 70 (61-80) <0.0001
thrombolysis 2 (17) 50 (20) n.s. 10 (26) 42 (19) n.s. 21 (24) 31 (18) n.s. 32 (23) 20 (18) n.s.
Laboratory
values
TC [mg/dl] 154 (137-180) 182 (159-213) n.s. 168 (153-192) 182 (157-214) n.s. 183 (158-212) 180 (156-212) n.s. 182 (158-212) 177 (155-211) n.s.
HbA1c [%] 5,8 (5,6-6,2) 5,8 (5,6-6,2) n.s. 5,9 (5,6-6,1) 5,8 (5,6-6,2) n.s. 5,9 (5,6-6,1) 5,8 (5,5-6,2) n.s. 5,9 (5,6-6,3) 5,8 (5,6-6,1) n.s.
Glc. [mg/dl] 125,5 (105-
164,5)
111,5 (98-135) n.s. 117 (105-141) 111 (97-13) n.s. 120 (106-149) 107 (95-133) 0.004 116 (98-146) 108 (96-132)
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8Table 2 Basic data and single factor analysis for tachy- and bradycardia (Continued)
TropI [ng/ml] 0,03 (0,01-0,06) 0,02 (0,01-0,04) n.s. 0,03(0,02-0,06) 0,02 (0,01-0,04) n.s. 0,03 (0,01-0,06) 0,02 (0,01-0,04) n.s. 0,03 (0,01-0,04) 0,02 (0,01-0,04) n.s.
CRP [mg/dl] 0,4 (0,4-0,5) 0,5 (0,4-0,9) n.s. 0,6 (0,4-1,3) 0,4 (0,4-0,8) n.s. 0,6 (0,4-1,2) 0,4 (0,4-0,7) n.s. 0,6 (0,4-1,0) 0,4 (0,4-0,5) n.s.
CREA [mg/dl] 1,1 (0,9-1,1) 1,0 (0,9-1,1) n.s. 1 (0,9-1,2) 1 (0,9-1,2) n.s. 1 (0,8-1,1) 1,1 (0,9-1,2) n.s. 1 (0,8-1,2) 1,1 (0,9-1,2) n.s.
TOAST:
atherothrombotic
2 (17) 46 (19) n.s. 4 (10) 44 (20) <0.0001 15 (17) 33 (20) 0.015 23 (16) 25 (22) n.s.
cardioembolic 5 (42) 91 (37) 27 (69) 69 (32) 45 (52) 51 (30) 60 (42) 36 (32)
lacunar 3 (25) 26 (11) 3 (8) 26 (12) 6 (7) 23 (14) 16 (11) 13 (11)
other 0 20 (8) 2 (5) 18 (8) 5 (6) 15 (9) 12 (8) 8 (7)
undetermined 2 (17) 61 (25) 3 (8) 60 (28) 16 (18) 47 (28) 31 (22) 32 (28)
ECG & TEE
VHF on ECG 4 (33) 68 (28) n.s. 11 (28) 61 (28) n.s. 24 (28) 48 (28) n.s. 42 (30) 30 (26) n.s.
PQ-time [ms] 160 (151-180) 174 (148-180) n.s. 160 (142-191) 178 (150-198) n.s. 166 (145-200) 174 (150-190) n.s. 174 (146-196) 172 (154-200) n.s.
QTc time [ms] 435 (422-475) 420 (401-475) n.s. 420 (402-439) 421 (402-442) n.s. 420 (399-440) 421 (405-442) n.s. 420 (400-442) 421 (404-441) n.s.
Impaired LV
function
1 (8) 21 (9) n.s. 4 (10) 18 (8) n.s. 9 (10) 13 (8) n.s. 9 (8) 14 (10) n.s.
Complications
HRD 2 (17) 22 (9) n.s. 11 (28) 13 (6) <0.0001
(OR 6.1;
2.6-14.9)
14 (16) 10 (6) 0.01 (OR 3.0;
1.3-7.1)
14 (10) 10 (9) n.s.
Infections (total) 7 (58) 98 (40) n.s. 24 (62) 81 (37) 0.007
(OR 2.7;
(1.3-5.4)
46 (53) 58 (34) 0.005 (OR 2.1;
1.3-3.6)
69 (49) 17 (12) <0.0001
(OR 5.4;
2.9-9.9)
Pneumonia 2 (17) 24 (10) n.s. 7 (18) 19 (9) 0.09 17 (20) 10 (6) 0.002 (OR 3.9;
1.7-8.7)
20 (14) 6 (5) 0.02 (OR
2.9; 1.2
-7.4)
Outcome
length of stay [d] 13 (10-20) 14 (10-20) n.s. 12 (9,5-21) 14 (10-17) n.s. 13 (9,5-18) 14 (10-17) n.s. 14 (10-18) 13 (9-18) n.s.
mRS ≥3 at three
months
7 (58) 118 (48) n.s. 25 (64) 100 (46) 0.05 (OR
2.1; 1.0-
4.2)
51 (59) 74 (44) 0.03 (OR 1.8;
1.1-3.1)
55 (48) 70 (49) n.s.
dead at three
months
1 (8) 18 (7) n.s. 4 (10) 15 (7) n.s. 9 (10) 10 (6) n.s. 8 (7) 11 (8) n.s.
aHT - arterial hypertension, COPD - chronic obstructive pulmonary disease, CHF - chronic heart failure, CHD - coronary heart disease, AF - atrial fibrillation, SaO2 - oxygen saturation, BP - blood pressure, HR - heart
rate, HRD - Heart rhythm disturbance, OR - odds ratio, CI - confidence interval. Ordinal/continuous variables are median (IQR), dichotomous variables are n(%).
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8stronger association for severe tachycardia and AF.
Tachycardia was associated with older age, higher
NIHSS scores on admission, larger infarctions on ima-
ging, history of hypertension, history of AF, higher HR
on admission and cardioembolic stroke etiology in single
factor analysis. The association was stronger for HR≥120
bpm than for HR≥100 bpm. Tachycardia was associated
with poor outcome at three months, and patients with
tachycardia more frequently died during their hospital
stay and at three months, however, these differences
were not significant.
Bradycardia <45 bpm occurred in 12 of 256 patients
(5%), and was only associated with HR on admission.
All other factors analysed did not significantly differ,
probably due to number of cases. Bradycardia <60 bpm
occurred in 114 patients (44%). Other than HR on
admission, there were no factors associated with this
endpoint.
After multiple logistic regression analysis neither
tachycardia nor bradycardia was predictive of infectious
complications. Infections were predicted by lesion size
(OR: 1.6, 1.2-2.1 per category, p = 0.0003) and admis-
sion and blood glucose on admission (1.01 per mg/dl,
1.0002-1.012, p = 0.04).
HRDs were predicted by lesion size (OR: 1.5, 1.01-2.2
per category, p = 0.04), tachycardia ≥120 bpm (OR: 3.2,
1.2-8.7) and cardioembolic stroke etiology (OR: 4.0, 1.4-
11.1, p = 0.008)
Dependency at three months was predicted by older
age (OR: 1.04, 1.02-1.07 per year, p = 0.0002), lesion
size (OR: 1.7, 1.3-2.2 per category, p = 0.0001) and ele-
vated blood glucose on admission (OR 1.01, (OR 1.001-
1.014, p = 0.02). There were trends for history of stroke
(p = 0.055) and infectious complications (p = 0.09) to
be associated with bad outcome.
The course of the mean HR within the first 24 hours
is displayed in figure 1.
Mean HR among all patients was highest on admis-
sion and sank during the first 24 h. HR dropped by an
average of 8 bpm from admission to 12 h, and remained
stable from there. The difference between HR on admis-
s i o n ,1 2ha n d2 4h o u r sw a sh i g h l ys i g n i f i c a n t( p<
0.0001).
Tachycardia according to textbook definition (HR
≥100 bpm) occurred in 87 of 256 patients (34%). More
severe tachycardia of HR ≥120 bpm occurred in 39
patients (15%). The onset of both, tachycardia and bra-
dycardia followed a mainly linearly pattern over the first
24 hours after admission; however tachycardia was more
frequent on admission compared with bradycardia.
Cumulative data on the time of the first detection of
tachycardia or bradycardia are given in figure 2.
Severe tachycardia was the rhythm disturbance most
frequently present on admission (17 of 39 patients,
33%), followed by mild tachycardia (22 of 87 patients,
33%) and mild bradycardia (30 of 114 patients, 26%).
Severe bradycardia occurred with the lowest percentage
on admission (3 of 12 patients, 25%).
Discussion
In our prospective study, significant tachycardia ≥120
bpm occurred in about 10% of acute stroke patients
within the first 24 hours after admission. Mainly
patients with AF were affected and those already having
Figure 1 Mean (± SD) heart rates on admission, at 4, 8, 12, 16,
20 and 24 hours. Mean values: Large black squares, plus/minus SD:
grey lines. There is significant reduction of the mean HR during the
first 24 hours after admission.
Figure 2 Cumulative percentage of high and low heart rate
violations over the first 24 hours after admission: Incidence of
HR threshold violations over time within the first 24 h after
admission. The total number of patients violating the threshold at
24 h is set 100%. Only the first threshold violation was recorded.
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Page 6 of 8high HR on admission. Patients with larger infarcts were
more likely to exhibit tachycardia. Other authors found
cardiac events mainly in patients with large infarctions
and high clinical severity [12]. Christensen et al. found
tachycardia ≥120 bpm to be related to poor outcome
[13] and Steger et al. found admission HR ≥100 bpm to
be independently related to mortality [14]. In our study,
outcome was worse in patients with tachycardia in sin-
gle factor analysis. However, these associations did not
withstand inclusion of age, lesion size and infectious
complications in the final regression model. This could
be due to significant interaction between all these
factors in acute stroke [15]. We assumed that severe
tachycardia would better discriminate between tachycardia
with and without prognostic importance, however this
may also have led to a case number too small to demon-
strate small effects. Patients with cardiac embolism fre-
quently have larger infarctions than other etiologic
subgroups. This could to be observed in our data as well,
and patients with AF were more likely to develop tachy-
cardia. Thus, inter correlation between tachycardia and
lesion size might be so strong that no independent effect
of tachycardia on outcome could be seen in our study.
Mean HR was highest on admission and decreased
within the next hours, which parallels the course of
blood pressure in the first hour after stroke [16], argue
for an intense stress reaction of the body leading to
sympathoadrenergic responses of the body. This reac-
tion is dependent on lesion size and on psychological
stress. The lesion size dependent reaction is in line with
other studies reporting stress reactions as causes of tro-
ponin increases [17,18] or increases in cardiac events
[19]. In the same direction points the observation that
higher blood glucose was associated with tachycardia in
single factor analysis and that blood glucose was asso-
ciated with poor outcome. This observation is very
much in line with other studies [20].
The occurrence of bradycardia was not predictable by
known outcome factors. Only lower HR on admission
was associated with bradycardia. On the one hand, bra-
dycardia <45 bpm was too rare in our cohort to reveal
robust results. On the other hand, mild tachycardia,
which occurred in 44% of all patients failed to be asso-
ciated with adverse outcome. Bradycardia occurred sig-
nificantly more frequent during night time than during
daytime. Taking the circadian rhythm into account, this
result is not surprising [16,21]. Mild tachycardia <60
bpm is not a useful threshold to guide clinical decision
making in the setting of acute stroke. In an unselected
stroke cohort, bradycardia seems to be mainly a benign
frequency reduction in most cases. Life threatening bra-
dycardias are singular events and are poorly predictable.
We did not find a significant preponderance for either
brain hemisphere to generate HR disturbances. There
was a non-significant trend towards more cardiac com-
plications in left hemispheric lesions which is in contrast
to other studies that described preponderance for right
hemispheric, especially insular, lesions [13,22,23]. The
difference may be explained because in a stroke cohort
without pre-selection of lesions of predefined brain
regions additional mechanisms such as size of the
infarction and individual risk profile cumulatively have a
greater role for HR disturbances than specific brain
regions. A limitation of our study was that we excluded
a significant proportion of patients with severe strokes,
namely those, who had to be intubated during the
admission process, or for invasive recanalisation proce-
dures, or those, who deteriorated within 24 hours from
admission (in total 23 patients, which accounts for
almost 10% of the entire cohort). These patients likely
would have exhibited a number of additional rhythm
disturbances, as we found lesion size and higher NIHSS
scores to be associated with tachycardia. Thus, the fre-
quency of arrhythmic periods in a general stroke popu-
lation was possibly underestimated. On the other side of
the spectrum of clinical severity 34 patients with mild
strokes had to be excluded as they were referred from
the stroke unit in stable conditions before the observa-
tion time was completed. This has possibly lead to a
slight overestimation of rhythm disturbances in the gen-
eral stroke population. Overall, the in- and exclusion of
patients on both sides of the broad spectrum of clinical
severity may have balanced out, and the detected fre-
quency of rhythm disturbances in stroke patients is a
good estimate for the frequency in the general stroke
population.
Conclusions
Serious HR threshold violations occur in more than 10%
of stroke patients thus justifying intensive monitoring of
all stroke patients. Current evidence argues mainly for a
significant stress reaction of the body as the reason for
HR increases after stroke. Pre-existing cardiac disease
further facilitates HR disturbances and cardiac events in
this setting. It is thus unlikely that treatment of rate dis-
turbances as such improve prognosis and prevent car-
diac events. However, to definitely answer this question,
randomised trials including active rate control arms are
needed.
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